HGH fragment 176-191

HGH Fragment 176-191 – growth hormone fragment for lipid metabolism studies

HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal section of human growth hormone (amino acids 176-191). Studies on animal models and adipocyte cultures have demonstrated its involvement in the modulation of lipid metabolism pathways, without simultaneous activation of the GH receptor in terms of growth stimulation. A substance intended exclusively for scientific research (Research Use Only) – it is not a medicinal product. Check out HGH Fragment 176-191 in the One Peptides catalogue and choose the reagent appropriate for your research project.

What is HGH Fragment 176-191?

HGH Fragment 176-191 is a peptide consisting of 16 amino acid residues, constituting a fragment of the human growth hormone (hGH) polypeptide chain spanning positions 176 to 191. This peptide was first synthesized and described in the 1990s by a research team led by Professor Gary Gross at Monash University in Australia. The aim of the study was to isolate the region of the hGH molecule responsible for the modulation of lipid metabolism.

In vitro studies on adipocyte cultures and in animal models showed that fragment 176-191 affects pathways related to lipolysis and fatty acid oxidation. Importantly, this peptide has no affinity for the growth hormone receptor (GHR) in terms of stimulating linear growth or tissue proliferation – which distinguishes it from the full hGH molecule. The mechanism of action has not yet been fully elucidated, but experimental data indicate the involvement of pathways independent of classical GHR/JAK2/STAT5 signaling.

HGH Fragment 176-191 variants available

The product is supplied with a Certificate of Analysis (CoA) containing purity data (HPLC) and proof of identity (MS). Full specifications and documentation are available on the product page.

HGH Fragment 176-191 5 mg – product characteristics

HGH Fragment 176-191 in the One Peptides catalogue is available in the form of a 5 mg lyophilisate. This amount is suitable both for preliminary in vitro experiments on adipocyte cultures (e.g. line 3T3-L1) and for in vivo studies in animal models of lipid metabolism. The lyophilisate ensures high stability during storage and transport. This quantity allows a series of experiments with multiple replicates to be carried out within one research project. If you have any questions regarding the selection of an experimental protocol, the One Peptides team is available for consultation.

How is HGH Fragment 176-191 different from similar peptides?

HGH Fragment 176-191 vs GLP-1
Both peptides are the subject of metabolic studies, but they involve different signaling pathways. HGH Fragment 176-191 affects processes related to lipid metabolism in adipocytes without interacting with the GLP-1R receptor. In contrast, GLP-1 activates the GLP-1R receptor and modulates pathways related to glucose metabolism in pancreatic beta cell models. Fragment 176-191 does not affect the somatotropic growth axis, while GLP-1 acts within the incretin axis. These peptides can be used complementarily in broad metabolic studies. See GLP-1 category

HGH Fragment 176-191 vs GW-501516 (Cardarine)
HGH Fragment 176-191 is a peptide, while GW-501516 is a synthetic PPARdelta receptor ligand – a molecule with a completely different chemical structure (it is not a peptide). In animal models, GW-501516 activates the nuclear receptor PPARdelta, modulating the expression of genes related to fatty acid oxidation and energy metabolism. Fragment 176-191 affects lipid metabolism through PPARdelta-independent mechanisms. The difference in the mechanism of action, chemical structure and site of action makes these substances interesting subjects for comparative research. See category GW-501516

FAQ – Frequently asked questions

1. Does HGH Fragment 176-191 work the same as full growth hormone?
NO. HGH Fragment 176-191 is only the C-terminal section of the hGH molecule (amino acids 176-191). In experimental studies, it does not show activation of the growth hormone receptor (GHR) in terms of stimulation of linear growth. Its action is limited to the modulation of lipid metabolism pathways, which distinguishes it from the full hGH molecule.

2. What experimental models is HGH Fragment 176-191 used for?
This peptide is used primarily in in vitro studies on adipocyte cultures (e.g. 3T3-L1 cell line) and in animal models. It is used to study lipolysis processes, fatty acid oxidation and metabolic pathways independent of classical GHR signaling.

3. Is HGH Fragment 176-191 a medicinal product?
NO. HGH Fragment 176-191 in the One Peptides catalogue is a substance intended exclusively for scientific research (Research Use Only). It is not a medicinal product, dietary supplement or food for consumption.

4. How should HGH Fragment 176-191 be stored?
The lyophilisate should be stored at -20°C, protected from moisture and light. After reconstitution, the solution should be divided into aliquots and stored at -20°C. Multiple freeze-thaw cycles should be avoided. For detailed information, see the product SDS.

5. Does HGH Fragment 176-191 affect IGF-1 concentration in animal models?
Experimental data indicate that HGH Fragment 176-191 does not stimulate IGF-1 secretion in a manner comparable to the full hGH molecule. This is consistent with the observation of lack of activation of the classical GHR/JAK2/STAT5 pathway. This property distinguishes fragment 176-191 from full-chain growth hormone and its analogues.

Quality and standards at One Peptides

Each batch of HGH Fragment 176-191 is analyzed by HPLC to confirm purity and by mass spectrometry (MS) to verify molecular weight and peptide identity. Each order is accompanied by a certificate of analysis (CoA) and a safety data sheet (SDS). Quality documentation is available for download on the product page, ensuring full transparency and repeatability of results.